CLDX Stock Cash Flow Statements

Celldex Therapeutics Quarterly Cash Flow Statements Chart

Quarterly

Annual

Stock-Based Compensation

Operating Cash Flow

Investing Cash Flow

Financing Cash Flow

Free Cash Flow

Capital Expenditure

Celldex Therapeutics Quarterly Cash Flow Statements Table

Quarterly

Annual

Unit: USD	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30	2023-06-30	2023-03-31	2022-12-31	2022-09-30	2022-06-30	2022-03-31	2021-12-31	2021-09-30	2021-06-30	2021-03-31	2020-12-31	2020-09-30	2020-06-30	2020-03-31	2019-09-30	2019-06-30	2019-03-31	2018-09-30	2018-06-30	2018-03-31	2017-09-30	2017-06-30	2017-03-31	2016-09-30	2016-06-30	2016-03-31	2015-09-30	2015-06-30	2015-03-31	2014-09-30	2014-06-30	2014-03-31	2013-09-30	2013-06-30	2013-03-31	2012-09-30	2012-06-30	2012-03-31	2011-09-30	2011-06-30	2011-03-31	2010-09-30	2010-06-30	2010-03-31	2009-09-30	2009-06-30	2009-03-31	2008-09-30	2008-06-30	2008-03-31	2007-09-30	2007-06-30	2007-03-31	2006-12-31	2006-09-30	2006-06-30	2006-03-31	2005-12-31	2005-09-30	2005-06-30	2005-03-31

cash flows from operating activities:
net income	-56,600,000	-53,796,000	-47,092,000	-42,121,000	-35,842,000	-32,808,000	-43,306,000	-38,260,000	-30,502,000	-29,361,000	-26,487,000	-26,784,000	-36,004,000	-23,050,000	-20,148,000	-20,452,000	-13,373,000	-16,538,000	-21,900,000	-14,224,000	-11,031,000	-12,625,000	-11,413,000	-11,779,000	-17,239,000	-7,243,000	-16,406,000	-118,132,000	-26,363,000	-28,566,000	-34,261,000	-29,598,000	-31,952,000	-34,673,000	-31,980,000	-32,359,000	-30,174,000	-28,081,000	-28,274,000	-29,903,000	-23,140,000	-19,016,000	-17,332,000	-15,027,000	-13,773,000	-13,516,000	-11,772,000	-10,236,000	-10,059,000	-9,087,000	-9,525,000	-6,582,000	-7,174,000	-8,704,123	-7,703,877	-7,656,158	-10,260,510	-22,130,682	-5,253,481	-5,505,246	-5,626,279	-6,212,075	-5,520,567	-5,670,299	-2,970,991	-3,979,697	-4,514,433	-4,733,940	-4,868,499
adjustments to reconcile net income to net cash from operating activities:
depreciation and amortization	873,000	867,000	819,000	786,000	797,000	775,000	759,000	767,000	756,000	726,000	673,000	671,000	741,000	811,000	777,000	752,000	764,000	775,000	755,000	861,000	1,148,000	1,165,000	1,208,000	1,153,000	1,352,000	835,000	993,000	1,028,000	1,025,000	1,001,000	1,366,000	701,000	692,000	742,000	767,000	712,000	672,000	603,000	582,000	579,000	479,000	475,000	468,000	503,000	529,000	544,000	566,000	568,000	562,000	580,000	700,000	908,000	619,000	650,404	685,596	709,473	707,924	353,126	701,419	657,286	578,523	590,039	542,256	490,242	473,080	449,039	455,369	344,900	342,351
amortization and premium of marketable securities	-1,688,000	-2,267,000	-3,363,000	-4,333,000	-4,740,000	-3,313,000	-2,179,000	-1,627,000	-1,160,000	-1,256,000	-522,000	58,000	536,000	772,000	198,000	-3,234,000	-125,000	-48,000	-307,000	-87,000	-272,000	-63,000										156,000	83,000	529,000
loss on sale or disposal of assets	2,000	4,000	4,000	4,000	0	8,000																	0	-18,000	25,000	101,000	1,059,000	10,000				0	4,000	70,000
stock-based compensation expense	9,191,000	9,316,000	9,780,000	9,620,000	7,640,000	7,202,000	7,212,000	7,121,000	5,217,000	4,340,000	4,508,000	4,496,000	3,454,000	3,153,000	3,140,000	3,029,000	1,509,000	1,275,000	1,257,000	1,250,000	721,000	687,000	707,000	1,464,000	1,693,000	1,793,000	2,048,000	2,488,000	2,739,000	3,450,000	3,539,000	3,796,000	3,973,000	3,940,000	3,869,000	2,527,000	2,281,000	1,958,000	1,511,000	1,250,000	2,016,000	676,000	708,000	526,000	447,000	641,000	570,000	553,000	580,000	583,000	644,000	970,000	618,000	751,530	1,112,470	1,846,822	816,421	1,622,380	97,492	76,490	98,897		413,402	275,640	264,255
changes in operating assets and liabilities:
accounts and other receivables	974,000	-364,000	152,000	682,000	1,137,000	-43,000	-2,376,000	-134,000	1,196,000	-967,000	-158,000	-92,000	146,000	-71,000	25,000	243,000	1,332,000	-26,000	-964,000	-509,000	779,000	-93,000	443,000	1,137,000	855,000					25,000	400,000			123,000						184,000				29,000	79,000	30,000	-41,000	80,000	81,000				-78,000	64,422	749,578
prepaid and other current assets	1,168,000	1,852,000	74,000	-14,351,000	599,000	-6,209,000	4,143,000	1,818,000	-2,783,000	2,722,000	-1,644,000	557,000	-1,337,000	-7,148,000	390,000	-717,000	593,000	-2,137,000	946,000	-844,000	-642,000	206,000			299,000	744,000																											-71,000								58,865
other assets	1,109,000	-662,000	0				0	0																					-67,000	0	199,000							17,000	16,000	16,000	17,000	62,000	188,000							181,000	191,000	182,000	180,000	180,336	180,664
accounts payable and accrued expenses	2,086,000	-8,718,000	7,994,000	6,707,000	1,714,000	-4,781,000	3,877,000	8,477,000	478,000	-3,448,000	2,403,000	1,582,000	1,876,000	-2,738,000	1,896,000	2,507,000	516,000	-1,266,000	774,000	1,118,000	599,000	-853,000																			2,845,000	-97,000	206,000												111,950	-4,431,576	4,573,573	1,285,405
other liabilities	-1,120,000	-604,000	-844,000	-2,691,000	-632,000	-1,469,000	-663,000	2,845,000	-395,000	-1,325,000	-536,000	-624,000	-387,000	4,273,000	-550,000	127,000	-3,404,000	-578,000	675,000	-79,000	-644,000	-768,000																-323,000	4,720,000	595,000	1,270,000	-354,000	516,000	47,000	-33,000	606,000
net cash from operating activities	-44,005,000	-54,372,000	-32,476,000	-55,337,000	-29,327,000	-40,638,000	-32,533,000	-18,993,000	-27,196,000	-28,569,000	-21,762,000	-35,192,000	-22,244,000	-24,534,000	-14,523,000	-16,372,000	-11,930,000	-18,084,000	-5,211,000	-11,861,000	-11,222,000	-12,110,000																																		-8,978,729						-1,973,205	-3,863,325	-4,249,613	37,086,462
capex	-728,000	-265,000	-756,000	-545,000	-274,000	-344,000	-666,000	-157,000	-410,000	-585,000	-235,000	-345,000	-673,000	-575,000	-354,000	-185,000	-143,000	-567,000	-247,000	-160,000	-910,000	-235,000																																		0						0	0	0	0
free cash flows	-44,733,000	-54,637,000	-33,232,000	-55,882,000	-29,601,000	-40,982,000	-33,199,000	-19,150,000	-27,606,000	-29,154,000	-21,997,000	-35,537,000	-22,917,000	-25,109,000	-14,877,000	-16,557,000	-12,073,000	-18,651,000	-5,458,000	-12,021,000	-12,132,000	-12,345,000																																		-8,978,729						-1,973,205	-3,863,325	-4,249,613	37,086,462
cash flows from investing activities:
sales and maturities of marketable securities	172,836,000	195,037,000	153,982,000	148,362,000	122,059,000	77,311,000	70,894,000	39,553,000	83,150,000	127,000,000	87,800,000	86,110,000	78,911,000	27,845,000	45,947,000	13,000,000	38,000,000	78,000,000	68,000,000	8,600,000	24,800,000	22,200,000	24,087,000	29,500,000	37,886,000	72,153,000	59,311,000	46,871,000	32,213,000	77,734,000	73,736,000	45,548,000	74,428,000	74,939,000	43,004,000	29,278,000	57,067,000	38,628,000	19,304,000	31,283,000	10,097,000	13,188,000	7,394,000	24,513,000	15,007,000	5,912,000	19,959,000	9,741,000	8,653,000	10,958,000	12,436,000	6,816,000
purchases of marketable securities	-122,258,000	-151,822,000	-129,179,000	-100,059,000	-168,508,000	-392,178,000	-241,389,000	-27,750,000	-81,576,000	-73,846,000	-56,352,000	-62,766,000	-52,957,000	-16,890,000	-64,539,000	-239,603,000	-51,769,000	-33,970,000	-36,927,000	-50,955,000
acquisition of property and equipment	-728,000	-265,000	-756,000	-545,000	-274,000	-344,000	-666,000	-157,000	-410,000	-585,000	-235,000	-345,000	-673,000	-575,000	-354,000	-185,000	-143,000	-567,000	-247,000	-160,000	-910,000	-235,000
net cash from investing activities	49,850,000	42,950,000	24,047,000	47,758,000			-171,161,000	11,646,000	1,164,000	52,569,000	31,213,000	23,068,000	25,281,000	10,380,000	-18,944,000	-226,787,000	-13,912,000	43,487,000	30,852,000	-42,506,000	-108,529,000	21,965,000	5,519,000	-7,959,000	16,296,000	-2,221,000	13,194,000	15,495,000	1,665,000	35,784,000	22,401,000	14,918,000	667,000	25,539,000															5,270,000				-115,000	-184,643	709,643
cash flows from financing activities:
net proceeds from stock issuances			0	0	0	432,298,000									0				-172,000	4,297,000	165,054,000	1,613,000	2,463,000	7,212,000	4,151,000	5,493,000	8,271,000	11,689,000	11,153,000	8,668,000	12,821,000	8,115,000			0	66,000	188,774,000				0	0	114,187,000	10,915,000	28,000	51,929,000	-9,000			385,000	429,000	187,000	11,000	467,922	10,078
proceeds from issuance of stock from employee benefit plans	63,000	202,000	386,000	1,239,000	3,712,000	3,814,000	1,152,000	257,000	133,000	694,000	1,395,000	2,306,000	71,000	304,000	426,000	2,004,000	-25,000	74,000	216,000	194,000	0	24,000	0	0	9,000	45,000	0	374,000	116,000	0	76,000	183,000	69,000	280,000	736,000	272,000	2,985,000	304,000	154,000	702,000	637,000	634,000	1,660,000
net cash from financing activities	63,000	202,000	386,000	1,239,000	3,712,000	436,112,000	217,374,000	257,000	133,000	694,000	1,395,000	2,306,000	71,000	304,000	426,000	271,897,000	-25,000	74,000	44,000	4,491,000	165,054,000	1,637,000	2,463,000	7,212,000	4,160,000	5,538,000	8,271,000	12,063,000	11,269,000	8,668,000	12,897,000	8,298,000	2,620,000	280,000	736,000	338,000	191,759,000	304,000	154,000	702,000	622,000	-9,086,000	114,509,000	9,580,000	-1,309,000	51,914,000	-23,000			334,000	381,000	141,000	-31,000			-89,019	10,851,388	128,856

net increase in cash and cash equivalents	5,908,000	-11,220,000	-8,043,000	-6,340,000	-72,338,000	80,263,000				24,694,000	10,846,000			-13,850,000	-33,041,000	28,738,000	-25,867,000	25,477,000	25,685,000	-49,876,000	45,303,000	11,492,000							-11,427,000	23,665,000	36,000				-14,793,000	-40,586,000	94,150,000					-49,727,000	50,730,000	4,624,000	-4,192,000	10,856,000										-9,682,608	40,961,292	6,509,014					-6,787,386	-6,287,203	36,336,485
cash and cash equivalents at beginning of period	0	28,356,000	0	0	0	34,814,000	0	0	0	29,429,000	0	0	0	39,143,000	0	0	0	43,836,000	0	0	0	11,232,000	0	0	24,310,000	0	0	40,288,000	0	0	42,461,000	0	0	72,108,000	0	0	28,020,000	0	0	169,402,000	0	0	24,897,000	0	0	11,899,000	0	0	21,287,000	0	0	57,002,000	0	-286	44,257,286	0	0	4,909,530	0	0	40,911,539	0	0	0	23,419,434	0	0	0	31,741,494
cash and cash equivalents at end of period	5,908,000	17,136,000	-8,043,000	-6,340,000	-72,338,000	115,077,000	13,680,000	-7,090,000	-25,899,000	54,123,000	10,846,000	-9,818,000	3,108,000	25,293,000	-33,041,000	28,738,000	-25,867,000	69,313,000	25,685,000	-49,876,000	45,303,000	22,724,000	-3,158,000	-11,789,000	31,533,000	-11,071,000	4,070,000	39,824,000	-11,427,000	23,665,000	42,497,000	-739,000	-30,543,000	63,025,000	-14,793,000	-40,586,000	122,170,000	-8,272,000	-16,105,000	56,902,000	-11,274,000	-49,727,000	75,627,000	4,624,000	-4,192,000	22,755,000	2,267,000	690,000	10,140,000	-5,330,000	-27,508,000	42,666,000	-5,648,000	-7,731,362	39,364,362	-9,682,608	40,961,292	11,418,544	-5,569,882	-6,664,255	32,573,796	-5,769,791	-6,787,386	-6,287,203	59,755,919	1,220,659	-4,829,823	-280,522	27,309,120
non-cash investing activities
accrued construction in progress	-455,000	504,000	-205,000	215,000	-88,000	105,000	-411,000	442,000	-88,000	134,000	75,000	-16,000	1,000	53,000	243,000				158,000	41,000	-440,000	462,000		-10,000	65,000			212,000
gain on fair value remeasurement of contingent consideration											0				-245,000	-1,901,000			18,000
proceeds from sale or disposal of assets											0				2,000	1,000	0	24,000	26,000	9,000																					0			62,000			4,000						0	-100	850,100
net cash (used in ) provided by investing activities						-315,211,000
gain on sale or disposal of assets											1,000	-56,000				1,000	0	-24,000
intangible asset impairment															0				14,500,000	0						0	0	18,677,000
non-cash income tax benefit															0				-939,000	0
net decrease in cash and cash equivalents								-7,090,000
litigation settlement payable
issuance of term loan																			0	0																											0	0	5,000,000
payment of term loan																			0	0
(gain) loss on fair value remeasurement of contingent consideration													-6,326,000	-536,000
(gain) loss on sale or disposal of assets																			-26,000	-9,000
other asset impairment																							0	0	1,800,000
loss on fair value remeasurement of contingent consideration																		483,000				234,000								1,000,000	3,400,000
amortization of intangible assets																										0	0	224,000	224,000	224,000	224,000	253,000	254,000	253,000	253,000	254,000	253,000	253,000	254,000	253,000	253,000	254,000	253,000	253,000	292,000	291,000	656,000	483,000	483,000	482,000	658,000	1,520,000	95,000	95,691	95,309	103,974	104,164	48,894
goodwill impairment																										0	0	90,976,000
non-cash supplemental disclosure
shares issued to former kolltan executive for settlement of severance																										8,000	19,000	38,000	39,000	54,000	209,000
loss/(gain) on fair value remeasurement of contingent consideration																								-1,017,000	1,519,000
net increase/(decrease) in cash and cash equivalents																									7,223,000
(gain)/loss on fair value remeasurement of contingent consideration
non-cash expense																																0	0	1,638,000	72,000	72,000	72,000
in-process research and development impairment
income tax benefit
investment in other
acquisition of property and equipment included in accounts payable and accrued expenses																													-12,000	-283,000	370,000	-43,000	-170,000	278,000	-465,000	-336,000	839,000
effect of exchange rate changes on cash and cash equivalents																																			0	0	15,000			1,000				1,000	-1,000	2,000				0
realized gain on sales and maturities of marketable securities
non-cash interest expense																																									0	41,000	56,000	58,000	54,000	57,000	58,000	57,000	135,000	182,000	182,000	182,000
payments of term loan
payments of other liabilities
loss on sales or disposal of assets
proceeds from sales or disposal of assets																																														11,000			64,000
realized (gain) loss on sales and maturities of marketable securities
(payments) issuance of term loan
payment of convertible subordinated debt
gain on sales or disposal of assets																																														23,000
realized loss on sales and maturities of marketable securities																																															-3,000	3,000	5,000
deferred revenue																																																						-105,059	191,059	110,958						-137,500	137,500	0	39,449,197	4,987,503	-12,501	4,987,499	25,795
payments of other long-term liabilities
other long-term liabilities																																																-166,000	288,000				13,000	19,405	30,595				-54,901	384,998	494,430	1,367,330	812,017	394,627	198,707
amortization of accretion of marketable securities																																																	244,000
amortization and accretion of marketable securities
loss on sales and maturities of marketable securities																																																		-9,000	10,000	21,000
supplemental disclosure of non-cash flow information
shares issued to executive officers																																																					0	0	250,000
in-process research and development																																																								0	0	14,755,908
cash acquired in avant merger, net of transaction costs
restricted cash deposits
related party loan due to medarex																																																								-30,280	42,478	148,115
shares received in exchange in the avant merger
shares issued to medarex in settlement of a payable																																																								0	0	3,038,617
future amounts payable to licensors
cash acquired in the acquisition of avant, net of transaction costs																																																								0	0	10,750,255
shares received in exchange in the acquisition of avant
shares received in exchange in the merger																																																								0	0	46,251,952
unpaid capitalized merger costs																																																										150,441
supplemental disclosure of cash flow information
cash paid for interest																																																							52,398				54,092	-8,769	31,699	16,495	25,521	25,997	35,737	18,514	38,009	20,777	31,108
impairment of investment in select vaccines limited
gain on impairment & disposal of assets																																																								4,345
deferred rent																																																								30,577	30,577	616
proceeds from sale of shares of select vaccines limited
proceeds from disposal of assets																																																								9,255
cash from investing activities																																																								-621,293	-155,672	10,737,322
net proceeds from stock issuance																																																								0
payments of loans payable
impairment of investment in select vaccines ltd
loss on disposal of assets																																																											1,866	0	74,148
other non-current assets																																																																					1,000
investment in select vaccines limited
proceeds from stock issuance																																																											2,835	0	1,709		7,752	0	6,145		3,383	0	2,055
proceeds from exercise of stock options and warrants																																																														13,898	214			11,138	28,501	0	427
payments of long-term liabilities
accounts receivable																																																												136,169	82,335					225,040	-166,349	439,380	1,313,899
cash flows from investing activity:
cash from investing activity
payment of long-term liabilities
adjustments to reconcile net income to cash
provided by operating activities:
(gain) loss on disposal of assets
stock-based compensation
changes in assets and liabilities
other non current assets
proceeds from the maturity of marketable securities
proceeds from (payment of) long-term liabilities
increase in cash and cash equivalents
income taxes paid
see note 9.
adjustments to reconcile net income to cash from operating activities:
cumulative effect of change in accounting principle
amortization of deferred compensation																																																																		175,000	121,000	121,000	121,000
changes in assets and liabilities, net of acquisition:
cash paid for acquisition of universal preservation technologies, inc. assets
purchases of treasury stock
see note 6.
supplemental disclosure of noncash financing activities
note payable from massdevelopment
see note 8.
increase in patents
changes in assets and liabilities:
decrease in cash and cash equivalents
inventories
increase in other assets
increase in patents and licenses
write-off of capitalized patent costs
prepaid expenses and other current assets
increase in other non-current assets
lease receivable
lease payable
adjustments to reconcile net income to net cash
used in operating activities:
decrease in restricted cash

We provide you with 20 years of cash flow statements for Celldex Therapeutics stock, allowing you to gain comprehensive visibility into the fundamentals of the company. Our detailed breakdowns include key financial metrics such as operating cash flows, cash levels, capital expenditures, profits, stock-based compensations and profit margins. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of Celldex Therapeutics stock. Explore the full financial landscape of Celldex Therapeutics stock with our expertly curated income statements.

The information provided in this report about Celldex Therapeutics stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.